NEOVACS news, videos and press releases
For more news please use our advanced search feature.
NEOVACS - More news...
NEOVACS - More news...
- Pharnext Strengthens its Ties With Néovacs to Secure the Next Steps in its Development
- NEOVACS SHARES TO RESUME TRADING ON MAY 20TH, 2020
- VALIDATION OF THE "RESTARTED" PLAN BY THE PARIS COMMERCIAL COURT
- DRAFT CONTINUITY PLAN // REVIEW HEARING SCHEDULED FOR MAY 6th, 2020
- EXTENSION OF THE OBSERVATION PERIOD IN THE FRAME OF REOGANIZATION PROCEEDINGS AND UPDATE ON RandD PROGRAMS
- OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS
- NEOVACS ANNOUNCES ITS 2019 HALF-YEAR RESULTS
- NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE OFFICER
- Neovacs : 2019 Financial Calendar
- NEOVACS ANNOUNCES THAT THE POSITIVE RESULTS OF ITS PROOF OF CONCEPT IN ALLERGIES WITH IL-4 / IL-13 KINOID HAVE TRIGGERED THE FIRST PAYMENT OF THE ANR GRANT
- NEOVACS ANNOUNCES THE APPOINTMENT of Dr. VIRGINIA PASCUAL AS MEDICAL AND SCIENTIFIC ADVISOR
- Neovacs to present the pre-clinical results of its IFNalpha Kinoid to treat type 1 diabetes - American Diabetes Association's 79th scientific sessions
- Neovacs to present the pre-clinical results of its therapeutic vaccine candidate IL-4 / IL-13 Kinoid to treat allergic Asthma
- Neovacs reports full-year 2018 Financial results and provides corporate update
- Néovacs : Agenda financier 2019
- Neovacs to host KOL Meeting to discuss its therapeutic vaccin IFNalpha Kinoid for lupus treatment - February 11th Paris
- Neovacs to present full results from the Phase IIb IFNalpha Kinoid clinical study at the 13th International Lupus Congress
- NEOVACS SECURES FINANCING FROM THE ANR - THE FRENCH NATIONAL RESEARCH AGENCY - TO DEVELOP THE IL-4/IL-13 KINOID AS AN ALLERGY TREATMENT
- Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha Kinoid
- Neovacs announces the patent filing in Europe and in the United States for its new therapeutic vaccine candidate Kinoid IL-4/IL-13 for the treatment of allergies
- Neovacs announces in vivo Proof of Concept success for its IL-4 / IL-13 Kinoid a new Therapeutic Vaccine to treat Mite-induced Asthma
- NEOVACS : HALF-YEAR 2018 FINANCIAL RESULTS
- NEOVACS ANNOUNCES THE CONTINUATION OF THE DEVELOPMENT OF ITS IFNalpha KINOID IN SOUTH KOREA WITH ITS PARTNER CHONG KUN DANG (CKD) PHARMACEUTICALS
- NEOVACS ANNOUNCES THAT ITS PARTNER BIOSENSE GLOBAL HAS EXERCISED ITS OPTION TO ACQUIRE THE EXCLUSIVE LICENCE FOR IFNalpha KINOID TO TREAT LUPUS IN CHINA
- NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFNalpha KINOID IN THE TREATMENT OF LUPUS
- NEOVACS STRENGTHENS INTELLECTUAL PROPERTY POSITION IN EUROPE AND JAPAN
- NEOVACS PROVIDES CORPORATE UPDATE AND REPORTS FULL-YEAR 2017 FINANCIAL RESULTS
- NEOVACS STRENGTHENS ITS INTELLECTUAL PROPERTY IN THE USA
- NEOVACS :2018 Financial Calendar
- Neovacs Announces Positive Data Review from Last IDSMB Review Prior to Final Results of Phase IIb Clinical Trial of IFNalpha Kinoid in Lupus
